54.12 0.00 (0.00%)
After hours: 4:36PM EDT
|Bid||51.42 x 200|
|Ask||58.00 x 100|
|Day's Range||53.70 - 54.90|
|52 Week Range||45.31 - 71.32|
|PE Ratio (TTM)||N/A|
|Earnings Date||Apr 25, 2018 - Apr 30, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||67.07|
Seattle Genetics' (SGEN) cancer drug, Adcetris, gets FDA approval to include fifth indication, frontline treatment of advanced classical Hodgkin lymphoma, in its label.
U.S. regulators on Tuesday approved Seattle Genetics Inc's Adcetris as part of a chemotherapy cocktail to treat advanced Hodgkin's lymphoma in newly diagnosed patients, making it the first new treatment in over 40 years. The widely expected approval opens up a key market for Seattle Genetics, which expects the drug to bring in $1 billion in sales within the next few years. "We're 100 percent launch-ready," Chief Executive Clay Siegall said in an interview ahead of the decision.
Seattle Genetics, Inc. announced today that the U.S. Food and Drug Administration has approved ADCETRIS in combination with chemotherapy in adult patients with previously untreated Stage III or IV classical Hodgkin lymphoma.
Seattle Genetics Inc. has appointed Alpna Seth to its board of directors, expanding the board to nine people including two women. Seth’s more than 20 years of experience in health care and biotechnology will help Seattle Genetics continue to build out its growing pipeline of cancer drugs, which includes four applications of its flagship drug Adcetris. “Seattle Genetics is on the cusp of a significant inflection point in its transition into a global, multi-product oncology company,” Seth said in a news release.
Alpna Seth's appointment expands the Seattle biotech's board to nine people including two women. Seth is chief operating officer at San Francisco-based Vir Biotechnology and previously was a senior vice president at Cambridge, Mass.-based Biogen.
Seattle Genetics, Inc. announced today that Alpna Seth, Ph.D. has been appointed to the company’s Board of Directors. Dr. Seth has more than 20 years of global experience in the healthcare and biotechnology/pharmaceutical industry, including senior leadership positions at Biogen.
Seattle Genetics, Inc. announced today that management will present at the Barclays Global Healthcare Conference 2018 on Wednesday, March 14, 2018 at 10:45 a.m. Eastern Time.
Seattle Genetics, Inc. today announced it has completed its previously announced acquisition of Cascadian Therapeutics, Inc. The most advanced program in Cascadian Therapeutics’ pipeline is tucatinib, an investigational oral tyrosine kinase inhibitor that is highly selective for HER2, a growth factor receptor that is overexpressed in multiple cancers, including breast, colorectal, ovarian and gastric....
Seattle Genetics, Inc. today announced the expiration of the tender offer by a wholly owned subsidiary, “Merger Sub”, for all of the shares of common stock of Cascadian Therapeutics, Inc.
Seattle Genetics (SGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Seattle Genetics, Inc. today announced dosing of the first patient in a phase 1 clinical trial evaluating the safety and tolerability of SGN-CD48A for patients with relapsed or refractory multiple myeloma .
NEW YORK, March 07, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
Seattle Genetics, Inc. announced today that management will present at the Cowen and Company 38th Annual Health Care Conference on Tuesday, March 13, 2018 at 9:20 a.m.
Seattle Genetics, Inc. today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 with respect to Seattle Genetics’ proposed acquisition of Cascadian Therapeutics, Inc.
Seattle Genetics Inc (NASDAQ:SGEN) files its latest 10-K with SEC for the fiscal year ended on December 31, 2017.
MADRID , Feb. 14, 2018 /PRNewswire/ -- PharmaMar (MCE: PHM) has announced today the signing of an exclusive licensing agreement with Seattle Genetics Inc. (SGEN: NASDAQ GS) under which Seattle Genetics ...
Stock Monitor: Seattle Genetics Post Earnings Reporting LONDON, UK / ACCESSWIRE / February 12, 2018 / Active-Investors.com has just released a free research report on Pieris Pharmaceuticals, Inc. (NASDAQ: ...
Pieris Pharmaceuticals, Inc. , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, ...
Pieris Pharmaceuticals, Inc. , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, and Seattle Genetics, Inc.
Seattle Genetics, Inc. today announced that its wholly-owned subsidiary, Valley Acquisition Sub, Inc., has commenced its previously announced tender offer for all outstanding shares of common stock of Cascadian Therapeutics, Inc.